Abstract
Background This study aimed to estimate syphilis prevalence among people who are pregnant with live births by race and ethnicity 2016–2023.
Methods We analyzed data on syphilis infection from U.S. birth certificates using a Bayesian mathematical model, adjusting for test sensitivity, specificity, and screening coverage. We calibrated the model under two scenarios: (1) assuming screening coverage is as estimated in Medicaid claims data and (2) assuming higher screening coverage than observed in Medicaid claims data. We compared the estimates to stillbirths attributable to syphilis reported through routine surveillance. We examined racial and ethnic disparities using the index of disparity.
Results In Scenario 1, syphilis prevalence among people who are pregnant with live births increased from 101.1 (95% uncertainty interval [UI]: 87.5–120.5) per 100,000 live births in 2016 to 533.4 (95% UI: 496.6–581.0) per 100,000 live births in 202. In Scenario 2, prevalence increased from 73.9 (95% UI: 51.2–130.0) per 100,000 live births to 378.1 (95% UI: 295.5–592.0) per 100,000 live births over the same period. With rising prevalence, relative racial and ethnic disparities narrowed over time. Prevalence was estimated to be higher among women with stillbirths compared to women with live births.
Conclusions In the United States, improved estimates of screening coverage are needed to understand the gaps in congenital syphilis prevention and to inform estimates of syphilis prevalence among pregnant persons.
One sentence summary line In the United States, we estimated an increasing syphilis prevalence among people who are pregnant, reaching 533 per 100,000 live births in 2023, with notable racial and ethnic disparities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available data from published literature cited and databases that were originally located at the National Center for Health Statistics (https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm), Sexually Transmitted Infections Surveillance 2023 (https://www.cdc.gov/sti-statistics/annual/index.html), and NCHHSTP AtlasPlus (https://www.cdc.gov/nchhstp/about/atlasplus.html?CDC_AAref_Val=https://www.cdc.gov/nchhstp/atlas/index.htm).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.